Literature DB >> 3116561

Anxiogenic effects of methyl-beta-carboline-3-carboxylate in a light/dark choice situation.

C Belzung1, R Misslin, E Vogel, R H Dodd, G Chapouthier.   

Abstract

Doses of benzodiazepine, clorazepate, and also of the inverse agonist of the benzodiazepine receptor, beta-CCM, which failed to present sedative or postictal depressive effects, were at first determined in a free exploratory situation. Then, the effects of clorazepate dosed at 1.0, 2.0 and 4.0 mg/kg and beta-CCM dosed at 1.0 and 2.5 mg/kg were studied in the light/dark box choice procedure. Clorazepate tended to produce an increase of the time spent by mice in the lit box as well as of the number of transitions between the two boxes, whereas the dose of 1.0 mg/kg of beta-CCM had opposite effects. The benzodiazepine antagonist RO 15-1788 completely counteracted the anxiolytic effects of clorazepate dosed at 2.0 mg/kg and the anxiogenic effects of beta-CCM.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3116561     DOI: 10.1016/0091-3057(87)90006-2

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  26 in total

1.  Benzodiazepine antagonist RO 15-1788 partly reverses some anxiolytic effects of ethanol in the mouse.

Authors:  C Belzung; E Vogel; R Misslin
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

2.  Behavioural effects of the benzodiazepine receptor partial agonist RO 16-6028 in mice.

Authors:  C Belzung; R Misslin; E Vogel
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

3.  A comparison of dehydroepiandrosterone and 7-keto dehydroepiandrosterone with other drugs that modulate ethanol intake in rats responding under a multiple schedule.

Authors:  Russell Joseph Amato; Mary Worrel Hulin; Peter John Winsauer
Journal:  Behav Pharmacol       Date:  2012-06       Impact factor: 2.293

4.  Experimental anxiety and antidepressant drugs: the effects of moclobemide, a selective reversible MAO-A inhibitor, fluoxetine and imipramine in mice.

Authors:  L de Angelis
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996 Aug-Sep       Impact factor: 3.000

5.  Effects of benzodiazepine agonist, inverse agonist and antagonist drugs in the mouse staircase test.

Authors:  D E Emmanouil; R M Quock
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

6.  Interaction of RO 15-4513 and ethanol on the behaviour of mice: antagonistic or additive effects?

Authors:  R Misslin; C Belzung; E Vogel
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

7.  LY 171555-induced hyperdefensiveness in the mouse does not implicate benzodiazepine receptors.

Authors:  C Belzung; S Cabib; L Fabiani; P Tolentino; S Puglisi-Allegra
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

8.  Glutaminase-deficient mice display hippocampal hypoactivity, insensitivity to pro-psychotic drugs and potentiated latent inhibition: relevance to schizophrenia.

Authors:  Inna Gaisler-Salomon; Gretchen M Miller; Nao Chuhma; Sooyeon Lee; Hong Zhang; Farhad Ghoddoussi; Nicole Lewandowski; Stephen Fairhurst; Yvonne Wang; Agnès Conjard-Duplany; Justine Masson; Peter Balsam; René Hen; Ottavio Arancio; Matthew P Galloway; Holly M Moore; Scott A Small; Stephen Rayport
Journal:  Neuropsychopharmacology       Date:  2009-06-10       Impact factor: 7.853

9.  Decreased immobility in swimming test by homologous interferon-alpha in mice accompanied with increased cerebral tryptophan level and serotonin turnover.

Authors:  Jianping Wang; Adrian J Dunn; Amanda J Roberts; Hua Zhang
Journal:  Neurosci Lett       Date:  2009-01-24       Impact factor: 3.046

10.  Pharmacological alterations of anxious behaviour in mice depending on both strain and the behavioural situation.

Authors:  Yan Clément; Anne-Marie Le Guisquet; Patrice Venault; Georges Chapouthier; Catherine Belzung
Journal:  PLoS One       Date:  2009-11-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.